Related Experiment Video
Updated: Sep 17, 2025
Heat-sensitive Moxibustion as a Traditional Chinese Medicine Therapy for Chronic Obstructive Pulmonary Disease Combined with Insomnia
Published on: May 30, 2025
Exploring pentoxifylline as an alternative treatment for dexamethasone in diabetic patients with COVID-19: a
Mohsen Gholinataj Jelodar1, Farahnaz Hoseinzadeh2, Samaneh Mirzaei3
1Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, School of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran.
Background:
Recent infectious disease outbreaks, notably COVID-19, have significantly affected society. Despite initial preventive measures and vaccination efforts, COVID-19 persist, requiring effective treatments. Commonly used corticosteroids face debate over their efficacy, with studies questioning their impact on COVID-19 outcomes and their association with hyperglycemia, particularly in diabetic patients. This complex interaction between COVID-19, diabetes, and corticosteroid use underscores the need for alternative treatments like pentoxifylline (PTXF) to manage inflammation and mitigate corticosteroid-induced hyperglycemia in diabetic patients.
Method:
This study aimed to assess the effectiveness of PTXF in diabetic COVID-19 patients through a randomized, controlled trial. Patients with specific criteria were recruited from two academic hospitals in Yazd, Iran and randomized to receive PTXF or dexamethasone along with other medications. Outcome measures included inflammatory markers, clinical symptoms, adverse events, and hyperglycemic-related risks.
Result:
The clinical trial, involving 47 diabetic patients, revealed that on the seventh day, the PTXF group exhibited lower mean levels of WBC, neutrophil, lymphocyte, IL6, and CRP compared to the dexamethasone group (p-value < 0.05). In addition, the rise in blood sugar during the illness was significantly lower in the PTXF group due to great importance and interest.
Conclusions:
PTXF may present promising evidence in improving COVID-19 patients by reducing inflammatory parameters, especially in diabetic patients.
Trial Registration:
Trial registry date: 2024-10-12, Trial Registry number: IRCT20190810044500N29.
More Related Videos
04:53Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach
Published on: October 18, 2024
11:34A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
Published on: April 11, 2025
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:24Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...